Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)Ciara Louise Freeman, Krina K. Patel, Paola Neri et al.|Blood|2025Cited by 1
Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)Susan Bal, Sham Mailankody, Luciano J. Costa et al.|Blood|2025Cited by 0
Trial in Progress: QUINTESSENTIAL—a Phase 2 study of Arlocabtagene Autoleucel (arlo-cel) in Patients with relapsed/refractory Multiple Myeloma (RRMM)Ciara L Freeman, Krina K. Patel, Nisha Joseph et al.|Transplantation and Cellular Therapy|2026Cited by 0